¢ß¾ËÅ׿ÀÁ¨ Revenue and Competitors

ALTEOGEN Inc., Daejeon(fifth-largest metropolis)-based in South Korea, is a leading biopharmaceutical company with a leading edge pipeline of novel biologics such as next generation biobetters including long-acting therapeutic proteins, Antibody-Drug Conjugate (ADC) therapeutic antibodies and monoclonal antibody biosimilars. The company was founded in 2008 and listed in KOSDAQ stock market (KRX:196170). Our innovative NexPâ„¢ fusion technology is applied to various proteins and peptides to allow longer activities in human beings. Long-acting human Growth Hormone, long-acting exenatide (for diabetes) and long-acting Factor VIIa (for hemophilia) are developed with the NexPâ„¢ fusion technology. Our proprietary ADC technology, NexMabâ„¢ ADC technology is well suited for the targeted therapy for the cancer drugs with lower side effect and better efficacy. With this NexMabâ„¢ ADC technology, we are developing ADC therapeutics for breast/gastric cancer and ovarian cancer. Alteogen's mostly distinguished Hybrozymeâ„¢ technology to a human hyaluronidase, which has been widely used to improve the absorption of drug biologics delivered via subcutaneous injection. The novel human hyaluronidase based on Hybrozymeâ„¢ technology showed improved enzymatic activity and thermal stability. Based on long and rich experiences, Alteogen has quickly developed its own cell lines with high expression, efficient process (upstream and downstream), and optimized analysis methods for monoclonal antibody biosimilars including Herceptin preparing for the phase 3 trials upon completion of global phase 2 testing, SC formulation of Herceptin biosimilar as well as working on Eylea biosimilar.